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Mark Thursz⇑
Department of Hepatology, Imperial College London, St. Mary’s Campus, Norfolk Place, London W2 1NY, United KingdomJanuary is traditionally a time for making (and breaking) New
Year’s resolutions. If your resolution is anything like mine it could
probably be summed up as eating less and exercising more than
the patients in my NAFLD clinic. Perhaps I could help you to ﬁnd a
more original resolution for 2012 – Get Active. No, I don’t mean
get physically active, I mean get politically active. The Hepatology
community is very effective when it comes to clinical care and
research excellence but I do not feel that we match up to other
specialties when it comes to lobbying, advocacy, and inﬂuencing
the political agenda in the health ﬁeld.
Is the political agenda really part of our remit? This is an
entirely legitimate and yet somewhat naive question. At the cur-
rent time, liver disease is now the ﬁfth most common cause of
mortality and in many European countries it differs from the
top four causes of mortality because it is the only one with a ris-
ing mortality rate. Despite this, Hepatology remains a relatively
small specialty with limited resources and very little support
from public health authorities or research funding agencies. If
we want to change this situation for the beneﬁt of our patients
then we need to get politically active.
It is difﬁcult to understand who sets the health agenda in
political circles. Globally the UN and its various institutions
appear to play an important role. The Millennium Development
Goals set HIV, TB, and malaria at the top of the health agenda over
a decade ago and this has been perpetuated by the Gates Founda-
tion and WHO. However, this prioritisation has had a negative
impact on other health issues. For example, it is now accepted
that there are a group of ‘neglected’ infectious diseases but
chronic viral hepatitis infection, affecting over half a billion peo-
ple worldwide, does not even make it into this second political
class of diseases. In 2010, EASL was delighted to see the adoption
of World Health Assembly resolution number 63.18 calling for
action on the prevention and treatment of viral hepatitis in
response to lobbying activities from numerous groups including
ourselves. However, 18 months later it is disappointing to see
that the Hepatitis section of WHO consists of only 2 individuals
compared to the thousands allocated to work on HIV, TB, cancer,
etc.
Over the last 12–18 months EASL has been working with
other professional and patient groups as part of the European
Chronic Disease Alliance (ECDA). The common denominatorsJournal of Hepatology 20
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Open access under CC BY-NC-ND license.which link these groups are the major determinants of chronic
disease in Europe: alcohol, tobacco, poor diet, and lack of physical
activity. ECDA is lobbying for the implementation of evidenced
based public health policies to tackle these issues. Potentially
the most important event on the global public health calendar
for 2011 should have been the UN High Level Meeting (HLM)
on chronic diseases in New York. Even though I am writing this
editorial in early September I can conﬁdently predict that the
outcome of the HLM will have been a disappointment. In my
opinion, it is unlikely that any of the carefully worded goals writ-
ten into the draft Political Declaration which commit govern-
ments to action will have been adopted. If by the time this
editorial appears I prove to be wrong then I will be content in
my embarrassment. The main obstruction to adoption of speciﬁc
goals in the document is lobbying activity by companies with
strong commercial interests. This is not, of course, a new situa-
tion. We have met similar opposition in the European Alcohol
and Health Forum where professional groups such as EASL are
only given the same level of inﬂuence as the alcohol industry.
The usual argument is that legislation which effectively reduces
the consumption of alcohol would threaten the economic pros-
perity of the European community. It is hard to see why this
argument holds sway when the European Commission’s own ﬁg-
ures suggest that the economic contribution of the alcohol indus-
try is €45 million per year whereas alcohol misuse costs the
community €450 million per year.
In 2011 a sustained advocacy campaign by the United Euro-
pean Gastroenterology Federation (UEGF) succeeded in generat-
ing a European Council Resolution on bowel cancer screening.
Although Council Resolutions are considered ‘soft law’ in Brussels
the reality is that policies advocated in these pieces of legislation
are invariably implemented at a member state level. UEGF should
certainly be applauded for this achievement. EASL, together with
the European Liver Patients Association (ELPA) are currently lob-
bying for similar legislation on screening for viral hepatitis. This is
clearly an uphill struggle, in part due to the unjustiﬁed stigmati-
sation of viral hepatitis but also due to the low volume of research
on viral hepatitis screening policies and cost-effectiveness. At a
European level the research agenda is embedded in the themes
of Framework Programme 7 (FP7) where a casual glance will con-
ﬁrm that liver disease is not a priority.
EASL has lobbied hard at the European Commission director-
ate for Research and Innovation (DG Research) for the past four
years. This lobbying activity is followed up with ﬁnancial support
for consortia applying for FP7 grant funding and we are proud of
the successes that the Hepatology community has achieved in the12 vol. 56 j 5–6
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last three years. Nevertheless, it is frustrating to see hypothe-
cated funding for diabetes, HIV, malaria, and TB and neurological
diseases with liver disease occasionally mentioned as an append-
age to other topics. Hypothecated funding for HIV research and
clinical care has reduced the mortality from AIDs in Europe so
that it is no longer considered a major public health threat. It is
therefore all the more exasperating that the politicians and public
health authorities are apparently unwilling to invest in liver dis-
ease to the same extent.
How should we address these inequities? One way is for EASL
to take the lead in setting and driving the political health agenda.
In this we will work with ELPA and, where expedient, with our
pharmaceutical company partners. This year EASL has appointed
Margaret Walker as Director of EU Public Affairs. Please join me6 Journal of Hepatology 2in welcoming her to the EASL team. Margaret will work with
Dominique Valla, our EU Policy Councillor, and Markus Peck-
Radosavljevic, EASL Vice-Secretary, on our EU agenda. However,
EASL cannot achieve the necessary seismic shifts in political atti-
tude on its own. Lobbying in Brussels needs to be supported and
ampliﬁed by lobbying activity targeted at member state govern-
ments, at regional and at local politicians and public health
organisations. EASL cannot reach these people but you can. So
instead of contemplating whether your New Year’s resolution
should be focussed on the excess kilos accumulated over the fes-
tive period, I would implore you to Get Politically Active.
To the EASL members and readers of the Journal of Hepatology
I wish you all a happy and productive 2012.012 vol. 56 j 5–6
